"In recent decades autism has been modeled as a brain-based, strongly genetic disorder. But a series of emerging findings and hypotheses support a broader model of the condition as genetically influenced and systemic. The heterogeneous biologies underlying autism may conceivably converge onto the autism profile via multiple mechanisms that all somehow perturb brain connectivity. Studying the interplay between the biology of intermediary mechanisms on the one hand and processing and connectivity abnormalities on the other may illuminate relevant final common pathways and contribute to focusing the search for treatment targets in this biologically and etiologically heterogeneous behavioral syndrome." Excerpted from a subject synopsis written by Martha Herbert, M.D., Ph.D.
To access the video clips, click the links beneath the Quicktime or Windows Media format icons for either the "Low" bandwidth (dial-up connection) or "High" bandwidth (DSL or Broadband) sizes.
All video clips are the copyright of the Foundation for Autism Information and Research (F.A.I.R. Autism Media) and are intended for informational purposes only. The content herein is not intended as medical advice.
Jon Poling, MD, PhD. & Richard Frye, MD, PhD. mitochondrial abnormalities in autism
Jon Poling, MD, PhD. is the Medical Director of the Athens Regional Medical Center Apheresis Unit, Clinical Assistant Professor Medical College of Georgia and a partner at Athens Neurological Associates. He is certified in MRI/CT interpretation by the American Society of Neuroimaging, is a diplomate of the American Association of Neuromuscular and Electrodiagnostic Medicine and is board certified by the American Board of Psychiatry and Neurology. Dr. Poling's education and training includes residency at the Johns Hopkins University Dept. of Neurology/Neurosurgery and completion of study for both his MD and PhD at the Georgetown University School of Medicine. Dr. Poling has co-authored numerous scientific papers published in peer-reviewed journals.
Richard Frye received his MD and PhD from Georgetown University. He completed his pediatric residency training at University of Miami and child neurology residency training at Children's Hospital Boston. Dr. Frye is also funded by the National Institutes of Health to study the brain function in individuals with dyslexia and is the medical director of the University of Texas medically-based autism clinic.
In this interview, Dr. Poling and Dr. Frye discuss mitochondrial abnormalities in children with autism.
Rob Coben received his PhD in 1991 and has been a licensed psychologist in the state of New York since 1994. He is the Director and Chief Neuropsychologist of a private clinic in NY, which is also an affiliated research site with NYU's Brain Research Lab. His post-doctoral training in clinical and rehabilitation neuropsychology was done at the UCLA Medical Center and Cedars-Sinai Medical Center in California. Dr. Coben is board-certified in EEG biofeedback (BCIA Associate Fellow) and a Diplomat of the QEEG Certification Board. He is a member in good standing of the American Psychological Association, International Neuropsychological Society, International Society for Neurofeedback and Research, and the American Association of Psychophysiology and Biofeedback.
In this interview, Dr. Coben discusses EEG Operant Conditioning (a form of biofeedback in which behavioral modification of the brain occurs) as a successful treatment for ADHD and Seizure Disorders.
Harry Schneider received his medical degree from Columbia University and completed his residency at Northwestern University. Dr. Schneider is an Associate Research Scientist in the Functional MRI Research Center of Columbia University. He is in private practice at the Center for Wellness adn Longevity in Plainview, NY, and uses the Defeat Autism Now! approach. Dr. Schneider served on the medical staff of North Shore University's Franklin General Hospital and South Nassau Communities Hospital, as well as serving as an Adjunct Professor for Clinical Training in the Family Practice Training Program at SNCH. He has participated in Tropical Medicine Research in Guatemala and Brazil for the World Health Organization and received research support as a Medical/Linguistic Consultant for Transcendent International's bilingual medical software. Dr. Schneider's background is as a linguist, with advanced degrees in language and linguistics, and he speaks multiple languages. He is in the process of obtaining a doctoral degree in Speech Language Pathology.
In this interview, Dr. Schneider discusses the discovery of language-specific areas in the brain of non-verbal children with autism and a practical application to treatment.
Woody McGinnis, MD was educated at Dartmouth College and the University of Colorado. After volunteer work in Peru, he practiced general medicine in Arizona. His interest in biochemical influences on behavior began with his son, Ryan. Since 2001, he has been a full-time researcher. He organized the Oxidative Stress in Autism Symposium in New York in 2005 and coordinates the multicenter Oxidative Stress in Autism Study. He is editorial advisor for the dedicated issue of Am J Biochem Biotech, April 2008.
In this interview, Dr. McGinnis discusses the role of Oxidative Stress on neurodevelopment and behavior in Autism.
Martha Herbert is an Assistant Professor of Neurology at Harvard Medical School, a Pediatric Neurologist at the Massachusetts General Hospital in Boston and at the Center for Child and Adolescent Development of Cambridge Health Alliance and a member of the Harvard-MIT-MGH Martinos Center for Biomedical Imaging. Prior to going to medical school she obtained a PhD in the History of Consciousness from the University of California, Santa Cruz. She has received the Cure Autism Now Innovator Award and directs the Cure Autism Now Foundation's Brain Development Initiative. She is the Co-Chair of the Environmental Health Project of the Autism Society of America. Her research program includes studying what makes some autistic brains unusually large, how the parts of the brain are connected and coordinated with each other, how to incorporate metabolic biomarkers into brain research and how we can develop measures sensitive to changes in brain function that could result from treatment interventions.